Effect of Curcumin on Systemic Lupus Erythematosus

Loma Linda University (LLU)

Status and phase

Terminated

Phase 2

Conditions

Systemic Lupus Erythematosus

Treatments

Drug: Curcumin supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT03953261

5190041

Details and patient eligibility

About

The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 18 or older
Diagnosed with Systemic Lupus Erythematous according to the 2012 Systemic Lupus International Collaborating Clinics Classification Criteria.
SLEDAI score of 6 or higher
Ability to take oral medication and be willing to adhere to the study drug regimen

Exclusion criteria

Inability to provide written consent for study participation
Use of curcumin supplements within 30 days of enrollment of study
Liver function disorders (AST/ALT > 2.5x upper limit of normal)
Pregnancy or lactation
Known allergic reactions to turmeric
Subjects who are admitted for recent hospitalization within past 60 days
Treatment with another investigational drug or other intervention within past 60 days
Subjects with end stage renal disease on dialysis
Subjects who lack the ability to provide consent